The medical community has historically defined, and treated cancer based on where it is found in the body, such as the breast, lung or Leukemia.
The FDA has recently started to approve treatments based on the genetic makeup of cancer rather than where the cancer is located.
Sequencing a patient’s DNA continues to become faster and cheaper. More patients now have a window into their genetic codes to better understand how changes in their genes can lead to diseases like cancer.
Sequencing helps us to understand if a genetic mutation in, say, breast cancer is similar to a genetic mutation linked to colon cancer. If that is the case, a patient with this type of breast cancer may benefit from a treatment used for colon cancer, rather than one used to treat breast cancer.
A very innovative path to treat successfully cancer and life-threatening illnesses
The human genome. So far, the most advanced test that is still in R&D but has been announced is a test that could detect up to 14 genes mutation. Until 2022 the only Leukemia test done were testing 2 genes mutation.
LENA Q51® by Alercell is detecting 51 genes mutation thus a very significant technological and medical advance.
The process is spectacular as the test can be administered in a qPCR machine and deliver the results within less than 3 hours. Compared to the current detection system for Leukemia the process is light speed ahead. In the traditional system to detect Leukemia, you need to undertake blood tests followed by bone marrow biopsy. It is time consuming, and it is a subjective interpretation as cytology remains to the human interpretation. This process takes an average of 3 to 6 weeks.
LENA Q51® takes less than 3 hours through a simple blood test
LENA Q51® is a breakthrough technology of Alercell-Oncology